Vericel raises 2026 guidance on strong momentum. The regenerative medicine company forecasted full-year revenue between $326 million and $336 million, reflecting confidence in its product portfolio. Record Q1 results drove the optimistic outlook, with MACI continuing to show strong performance in the orthopedic market. A major catalyst emerges as government-backed BARDA procurement of NexoBrid is expected to commence in the second half of 2026, potentially unlocking significant commercial opportunities. NexoBrid, the company's advanced wound care solution, addresses a substantial market need and represents a meaningful growth driver. The timing of BARDA procurement could accelerate adoption and establish strong market penetration.
Post from MarketNews_en
Log in to interact with content.